Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

Presentation TCT 2016

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Presenter: Stuart J. Pocock, Jan G. P. Tijssen, David J. Cohen

November 01, 2016

Presentation Fellows 2016

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: Gary S. Mintz, David J. Cohen

April 16, 2016

News Daily News

Incluso con Más Experiencia la TAVR Transapical No ofrece una Mejor Calidad de Vida que la Cirugía

Caitlin E. Cox

June 15, 2015

News Daily News

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

Caitlin E. Cox

June 15, 2015

Presentation Fellows 2015

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: Gary S. Mintz, Ajay J. Kirtane, David J. Cohen

May 16, 2015

Presentation TCT 2014

TCT 347: Assessment of Intravascular Ultrasound-Derived Minimal Lumen Area and Fractional Flow Reserve to Evaluate Functionally Significant Coronary Artery Disease: A Meta-analysis

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Jae-Sik Jang, MD

September 13, 2014

Presentation TCT 2014

TCT 252: Preprocedural Statin Administration Benefit According to Baseline Renal Function: A Meta-analysis of Randomized Controlled Trials

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Daniele Giacoppo, MD

September 13, 2014

Presentation TCT 2014

Meta-analysis: From PRISMA Standards to Utility in Guiding Practice

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Sripal Bangalore

September 13, 2014

Presentation TCT 2014

Definition, Reliability, and Interpretation of Surrogate Endpoints

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen

September 13, 2014

Presentation TCT 2014

Subgroup Analyses: Proceed (and Interpret) with Caution

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen, Eugene H. Blackstone

September 13, 2014

Presentation TCT 2014

Randomized vs Observational Studies: Strengths and Weaknesses

Presenter: Stuart J. Pocock, William S. Weintraub, David J. Cohen

September 13, 2014

News Daily News

Link Between PCI Volume and Outcomes Remains Intact

Todd Neale

September 13, 2014

News Daily News

El Nexo que existe entre Volumen PCI y Resultados Sigue Intacto

Todd Neale

September 13, 2014

Presentation TVT 2014

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Presenter: David J. Cohen

June 07, 2014

Presentation Fellows 2014

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Presenter: David Cohen

April 12, 2014

News Daily News

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

News Daily News

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

July 25, 2013

News Daily News

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

July 25, 2013

Advertisement

Strategy Trials: ISCHEMIA/EXCEL/FREEDOM: Strengths and Weaknesses

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

Incluso con Más Experiencia la TAVR Transapical No ofrece una Mejor Calidad de Vida que la Cirugía

Even With More Experience, Transapical TAVR Offers No Better QoL Than Surgery

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

TCT 347: Assessment of Intravascular Ultrasound-Derived Minimal Lumen Area and Fractional Flow Reserve to Evaluate Functionally Significant Coronary Artery Disease: A Meta-analysis

TCT 252: Preprocedural Statin Administration Benefit According to Baseline Renal Function: A Meta-analysis of Randomized Controlled Trials

Meta-analysis: From PRISMA Standards to Utility in Guiding Practice

Definition, Reliability, and Interpretation of Surrogate Endpoints

Subgroup Analyses: Proceed (and Interpret) with Caution

Randomized vs Observational Studies: Strengths and Weaknesses

Link Between PCI Volume and Outcomes Remains Intact

El Nexo que existe entre Volumen PCI y Resultados Sigue Intacto

The TAVR Economic Value Proposition The Impact of Valve Costs, Complications, QOL Benefits, and Reimbursement Strategies

Essentials of Clinical Trial Design: Statistics 101 for the Interventionalist

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

For Inoperable Patients, TAVR Carries Benefits but Raises Lifetime Costs

En Pacientes Inoperables, la TAVR produce Beneficios pero Dispara el Gasto de por Vida

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content